Interferon alfa-n1

Summary

Interferon alfa-n1 (Wellferon) is a highly purified blend of natural human alpha interferons derived from Namalwa lymphoblastoid cells. It exhibits antiviral, antiproliferative, and immunomodulatory properties and has been used in the treatment of chronic hepatitis C and certain viral conditions. It is a multi-subtype natural interferon product distinct from recombinant interferon alfa-2a or alfa-2b.

Mechanism of Action

Binds to cell surface type I interferon receptors (IFNAR1/IFNAR2), activating JAK-STAT signaling pathway (JAK1/TYK2), leading to transcription of interferon-stimulated genes (ISGs) that confer antiviral, antiproliferative, and immunomodulatory effects.

Routes of Administration

Goals & Uses

• Chronic Hepatitis C treatmentAntiviralHigh
• ImmunomodulationImmunologyModerate
• Antiviral activity (general)AntiviralModerate
• Antiproliferative / oncology supportOncologyModerate

Contraindications

• Severe psychiatric disorders (uncontrolled)PsychiatryHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Hypersensitivity to interferon alfa or any excipientAllergy/ImmunologyHigh
• Autoimmune hepatitisHepatic / AutoimmuneHigh
• Decompensated liver diseaseHepatic ImpairmentHigh

Adverse Effects

• Hematologic toxicity (neutropenia, thrombocytopenia, anemia)HematologicCommon
• Depression and neuropsychiatric effectsNeuropsychiatricCommon
• Injection site reactionsLocalCommon
• AlopeciaDermatologicUncommonHair loss
• Thyroid dysfunctionEndocrineUncommon
• Flu-like syndrome (fever, chills, myalgia, fatigue)SystemicCommon

Drug Interactions

• Myelosuppressive agentsHigh
• RibavirinModerate
• TheophyllineModerate
• MethadoneModerate
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Pre-existing cardiac diseaseCardiovascularRelative
• Elderly patients (≥65 years)Age RelatedRelative

Regulatory Status

• European UnionWithdrawnApproved: Chronic hepatitis CPreviously marketed in some EU member states; largely withdrawn as DAAs became standard of care.
• United StatesUnapprovedInterferon alfa-n1 (Wellferon) was not approved by the FDA; recombinant alfa-2a and alfa-2b are the approved forms in the US.
• United KingdomApprovedApproved: Chronic hepatitis CWellferon was approved by UK authorities for chronic hepatitis C; marketing status may be discontinued.

Approved in Canada and some other countries (e.g., UK) for chronic hepatitis C. Not FDA-approved in the United States as a standalone product. Marketing has been limited or discontinued in several jurisdictions.

Evidence & Sources

No sources recorded yet.